SCHEMBL2092811

SCHEMBL2092811

Cc1cc(Oc2ccc3cc(O)ccc3n2)cc(C)c1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.50
ALDH1A1 P00352 2/20 0.50
HSD17B10 Q99714 2/20 0.50
HPGD P15428 1/20 0.50
TTR P02766 2/20 0.43
ESR1 P03372 3/20 0.41
ESR2 Q92731 3/20 0.41
MCL1 Q07820 1/20 0.37
BAK1 Q16611 1/20 0.37
PDE4B Q07343 3/20 0.36
PLA2G10 O15496 1/20 0.35
CYP1A2 P05177 1/20 0.35
ABL1 P00519 1/20 0.34
ABCB1 P08183 1/20 0.34
BCR P11274 1/20 0.34
MAPT P10636 2/20 0.34
LMNA P02545 1/20 0.34
GAA P10253 1/20 0.34
ALOX15 P16050 1/20 0.34
CASP1 P29466 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2092806 0.82 PDE4B (0.36) KDM4EALDH1A1HSD17B10HPGDMCL1
SCHEMBL3665193 0.82 ESR2 (0.53) KDM4EALDH1A1HSD17B10HPGDTTR
SCHEMBL3316262 0.80 ALDH1A1 (0.61) KDM4EALDH1A1HSD17B10HPGDESR1
SCHEMBL27644899 0.80 LMNA (0.44) KDM4EALDH1A1HSD17B10HPGDTTR
SCHEMBL2097582 0.79 ESR1 (0.41) KDM4EALDH1A1HSD17B10HPGDTTR
SCHEMBL3317035 0.77 HTT (0.45) KDM4EALDH1A1HSD17B10HPGDESR1
SCHEMBL1238150 0.75 ESR1 (0.50) KDM4EALDH1A1HSD17B10HPGDTTR
SCHEMBL29768705 0.75 ESR1 (0.50) KDM4EALDH1A1HSD17B10HPGDTTR
SCHEMBL2093017 0.72 ESR2 (0.44) KDM4EALDH1A1HSD17B10HPGDTTR
SCHEMBL3314874 0.72 KMT2A (0.44) KDM4EALDH1A1HSD17B10HPGDESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 KDM4E 4578/4885ALDH1A1 412/4885HSD17B10 363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.